Ontology type: schema:ScholarlyArticle Open Access: True
2006-12
AUTHORSAmit Agrawal, John F R Robertson, K L Cheung
ABSTRACTBACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal. METHODS: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS software for statistical analysis. RESULTS: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64 (28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively. CONCLUSION: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances. More... »
PAGES40
http://scigraph.springernature.com/pub.10.1186/1477-7819-4-40
DOIhttp://dx.doi.org/10.1186/1477-7819-4-40
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1020103401
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16822312
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Agrawal",
"givenName": "Amit",
"id": "sg:person.01036236301.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Robertson",
"givenName": "John F R",
"id": "sg:person.07764637207.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Cheung",
"givenName": "K L",
"id": "sg:person.016477423232.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1023/a:1023983032625",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001709392",
"https://doi.org/10.1023/a:1023983032625"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1987.14",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004831077",
"https://doi.org/10.1038/bjc.1987.14"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1987.14",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1004831077",
"https://doi.org/10.1038/bjc.1987.14"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(74)91364-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006753414"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011360956"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/cncr.11764",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013693142"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1005828731462",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018344209",
"https://doi.org/10.1023/a:1005828731462"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00689685",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019965929",
"https://doi.org/10.1007/bf00689685"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-04-0110",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1021321766"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1992.153",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022813323",
"https://doi.org/10.1038/bjc.1992.153"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1992.153",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022813323",
"https://doi.org/10.1038/bjc.1992.153"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1677/erc.1.01108",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025619483"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1677/erc.1.01108",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025619483"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0959-8049(97)00178-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1030310702"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-004-4776-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031540377",
"https://doi.org/10.1007/s10549-004-4776-0"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/0360-3016(83)90286-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031856738"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2005.05.145",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037375825"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.amjsurg.2004.06.017",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048578512"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3109/02841869609083979",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049839415"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1160/th03-07-0467",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1063289951"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2003.09.099",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064203852"
],
"type": "CreativeWork"
}
],
"datePublished": "2006-12",
"datePublishedReg": "2006-12-01",
"description": "BACKGROUND: In a significant proportion of metastatic breast cancer (MBC) patients whose tumour has progressed within 6 months of endocrine therapy (de novo resistance), it is generally believed that the chance of achieving clinical benefit (CB) with further endocrine therapy is minimal.\nMETHODS: Data was retrieved from a prospectively updated database of metastatic breast cancer. Relevant data was exported to SPSS software for statistical analysis.\nRESULTS: In oestrogen receptor (ER) positive MBC patients with assessable disease, CB was achieved in 159 (71.3%) (1st line) patients. When these patients were put on further endocrine therapy, the CB rates were 63.2% (on 2nd line), 46.1% (on 3rd line) and 20% (on 4th line) with a median duration of response (DOR) in those with CB of 22, 12, 11 and 15 months respectively. The remaining 64 (28.7%) patients had de novo resistance on 1st line endocrine therapy. Seventeen of these patients were treated with further endocrine therapy. The CB rates were 29.4% (on 2nd line) and 22.2% (on 3rd line) with a median DOR in those with CB of 22.7 months and 14 months respectively.\nCONCLUSION: The chance of further endocrine response continues to decrease with each line of therapy, yet CB is still seen with reasonable duration even with a 4th line agent. In addition, further endocrine response, with long duration, can be seen in a significant proportion of patients who have developed de novo resistance to 1st line endocrine therapy. The use of further endocrine therapy should not be excluded under these circumstances.",
"genre": "research_article",
"id": "sg:pub.10.1186/1477-7819-4-40",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1032056",
"issn": [
"1477-7819"
],
"name": "World Journal of Surgical Oncology",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "4"
}
],
"name": "\"Resurrection of clinical efficacy\" after resistance to endocrine therapy in metastatic breast cancer",
"pagination": "40",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"5fc9373a75c003d5de9058e776f1bc16a4b38034959edea2ba7ff182331edee4"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16822312"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101170544"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/1477-7819-4-40"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1020103401"
]
}
],
"sameAs": [
"https://doi.org/10.1186/1477-7819-4-40",
"https://app.dimensions.ai/details/publication/pub.1020103401"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T18:20",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000512.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1186%2F1477-7819-4-40"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-40'
This table displays all metadata directly associated to this object as RDF triples.
145 TRIPLES
21 PREDICATES
47 URIs
21 LITERALS
9 BLANK NODES